Table 2.
Univariate analysis of preoperative predictive factors
| Factor | 5‐year survival (N = 38) | <5‐year survival (N = 133) | P‐value |
|---|---|---|---|
| Age (years), median (range) | 65 (55–81) | 67 (46–83) | 0.211 |
| Sex (M/F) | 24/14 | 70/43 | 0.894 |
| BMI (kg/m2), median (range) | 23.8 (16.4–40.0) | 23.9 (15.8–33.4) | 0.650 |
| Surgical procedure, N (%) | 0.226 | ||
| Pancreaticoduodenectomy | 20 (52.6) | 76 (67.3) | 0.121 |
| Distal pancreatectomy | 15 (39.5) | 33 (29.2) | 0.314 |
| Total pancreatectomy | 3 (7.9) | 4 (3.5) | 0.369 |
| NACRT, N (%) | 12 (31.5) | 11 (9.7) | 0.003* |
| Tumor size (cm), N (%) | |||
| <4.0 | 35.0 (92.1) | 101.0 (89.4) | 0.628 |
| ≥4.0 | 3.0 (7.9) | 12.0 (10.6) | 0.628 |
| Total bilirubin level (mg/dL), median (range) | 0.8 (0.3–4.2) | 0.9 (0.4–6.5) | 0.252 |
| Albumin level (g/L), median (range) | 4.0 (2.6–4.7) | 3.8 (2.7–4.8) | 0.011* |
| Globulin level (g/L), median (range) | 2.9 (0.3–4.0) | 2.9 (1.9–4.2) | 0.981 |
| Albumin‐to‐globulin ratio, median (range) | 0.3 (0.1–1.7) | 0.3 (0.1–2.5) | 0.129 |
| Cholinesterase level (U/L), median (range) | 248.0 (76.0–394.0) | 241.0 (72.0–427.0) | 0.664 |
| Total cholesterol level (mg/dL), median (range) | 164.0 (94.0–257.0) | 176.0 (94.0–303.0) | 0.658 |
| WBC count (×103/μL), median (range) | 4550 (1400–8400) | 5300 (2000–12,400) | 0.014* |
| Neutrophil count (×103/μL), median (range) | 2881 (1106–7039) | 3088 (1016–9696) | 0.057 |
| Lymphocyte count (×103/μL), median (range) | 1093 (164–2144) | 1312 (453–3248) | 0.019* |
| Neutrophil‐to‐lymphocyte ratio, median (range) | 2.3 (1.0–7.4) | 2.3 (0.5–11.0) | 0.584 |
| Platelet count (×103/μL), median (range) | 197 (93–410) | 216 (91–411) | 0.085 |
| CRP level (mg/L), median (range) | 0.2 (<0.1–9.6) | 0.2 (<0.1–5.2) | 0.545 |
| Fibrinogen level (mg/dL), median (range) | 330.0 (130.0–714.0) | 355.0 (182.0–669.0) | 0.190 |
| CEA level (ng/mL), median (range) | 2.6 (0.8–52.6) | 3.0 (0.9–60.9) | 0.425 |
| CA 19‐9 level (U/mL), median (range) | 45.0 (1.0–7240.0) | 88.0 (1.0–8820.0) | 0.814 |
| Elastase‐1 level (ng/dL), median (range) | 101.0 (40.0–1431.0) | 215.0 (31.0–5230.0) | 0.112 |
| DUPAN‐2 level (U/mL), median (range) | 42.0 (25.0–3930.0) | 175.0 (25.0–18,400.0) | 0.186 |
| SPAN‐1 level (U/mL), median (range) | 25.0 (6.0–228.0) | 71.0 (6.0–3100.0) | 0.091 |
| PNI, median (range) | 45.4 (34.8–54.6) | 45.4 (32.2–62.3) | 0.214 |
| CRP‐to‐albumin ratio, median (range) | 0.040 (0.010–2.230) | 0.040 (0.002–1.410) | 0.724 |
| mGPS (0/1/2), N | 31/7/0 | 78/30/5 | 0.080 |
BMI, body mass index; CA 19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CRP, C‐reactive protein; DUPAN‐2, Duke pancreatic monoclonal antigen type‐2; F, female; M, male; mGPS, modified Glasgow Prognostic Score; NACRT, neoadjuvant chemoradiotherapy; PNI, prognostic nutritional index; SPAN‐1, s‐pancreas antigen‐1; WBC, white blood cell.
P < 0.05.